Your trusted source for investing success since 2007. Renowned for our market outlook reports and investing guides.
Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting
Cyclacel Pharmaceuticals (NASDAQ:CYCC) (NASDAQ:CYCCP) a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced results from a Phase 1 safety, pharmacokinetic and pharmacodynamic study of CYC065, the Company’s novel cyclin dependent kinase, or CDK2/9 inhibitor, in patients with advanced …
Cyclacel Pharmaceuticals (NASDAQ:CYCC) (NASDAQ:CYCCP) a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced results from a Phase 1 safety, pharmacokinetic and pharmacodynamic study of CYC065, the Company’s novel cyclin dependent kinase, or CDK2/9 inhibitor, in patients with advanced cancers. Data were reported at an oral presentation on Sunday, April 15, at 3:35 PM CT at the American Association for Cancer Research (AACR) Annual Meeting held in Chicago, IL.
As quoted in the press release:
“Our findings show that CYC065 is effective in suppressing the cancer survival protein Mcl-1 in peripheral blood for at least 24 hours,” said Geoffrey Shapiro, MD, PhD, Director, Early Drug Development Center, Dana-Faber Cancer Institute and Professor of Medicine, Harvard Medical School, Boston, MA. “The durable target inhibition achieved at the recommended Phase 2 dose provides a rationale to further evaluate this novel agent in Mcl-1, MYC or cyclin E amplified tumors.”
“The clinical data support biomarker-driven clinical development of CYC065 in selected patient populations,” said Spiro Rombotis, President and Chief Executive Officer of Cyclacel. “In addition, the durable suppression of the Mcl-1 survival protein presents an exciting opportunity to combine CYC065 with other agents targeting the apoptosis pathway, such as venetoclax. We will soon be starting a clinical study testing CYC065 in combination with venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia.”
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 1959.29 | +17.80 | |
Silver | 23.19 | +0.05 | |
Copper | 3.66 | -0.02 | |
Palladium | 1713.17 | 0.00 | |
Platinum | 1087.26 | 0.00 | |
Oil | 69.69 | -2.98 | |
Heating Oil | 2.28 | -0.08 | |
Natural Gas | 2.31 | -0.11 |
DOWNLOAD FREE REPORTS
BROWSE COMPANIES BY SECTOR
- Agriculture Investing
- Phosphate Investing
- Potash Investing
- Base Metals Investing
- Copper Investing
- Iron Investing
- Lead Investing
- Nickel Investing
- Zinc Investing
- Battery Metals Investing
- Cobalt Investing
- Graphite Investing
- Lithium Investing
- Manganese Investing
- Vanadium Investing
- Critical Metals Investing
- Magnesium Investing
- Rare Earth Investing
- Scandium Investing
- Tantalum Investing
- Tellurium Investing
- Tungsten Investing
- Energy Investing
- Oil and Gas Investing
- Uranium Investing
- Gem Investing
- Diamond Investing
- Industrial Metals Investing
- Aluminum Investing
- Chromium Investing
- Coal Investing
- Molybdenum Investing
- Tin Investing
- Precious Metals Investing
- Gold Investing
- Palladium Investing
- Platinum Investing
- Silver Investing
- 3D Printing Investing
- Bitcoin Investing
- Blockchain Investing
- Cleantech Investing
- Cloud Investing
- Cryptocurrencies
- Data Investing
- Emerging Tech Investing
- Artificial Intelligence Investing
- Mobile Investing
- Robotics Investing
- Fintech Investing
- Gaming Investing
- Esports Investing
- Nanoscience Investing
- Graphene Investing
- Nanotech Investing
- Security Investing
Featured Pharmaceutical Investing Stocks
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.